Zafgen's value halves as it gives up on lead obesity candidate

21 July 2016

Obesity drug developer Zafgen (Nasdaq: ZFGN) saw its share price slide by more than 50% on Wednesday after it announced that it was ceasing development of its lead candidate beloranib in Prader-Willi syndrome (PWS).

The US-based company has told shareholders that this blow will result in a reduction of Zafgen’s workforce of 34% including the departure of senior staff members, as it refocuses its resources on development of a differentiated second-generation MetAP2 inhibitor, ZGN-1061, in severe and complicated obesity.

An inability to assure patient safety is the reason for the development of beloranib being halted, Zafgen’s chief executive Thomas Hughes wrote in a letter addressed to the “PWS community” following the announcement.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK